149 related articles for article (PubMed ID: 8263015)
21. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
22. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
[TBL] [Abstract][Full Text] [Related]
23. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
24. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
[TBL] [Abstract][Full Text] [Related]
25. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
26. Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen.
Bolis G; Scarfone G; Luchini L; Ferraris C; Zanaboni F; Presti M; Giardina G; Villa A; Parazzini F
Eur J Cancer; 1994; 30A(12):1764-8. PubMed ID: 7880602
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis.
Nishimura S; Tsuda H; Hashiguchi Y; Kokawa K; Nishimura R; Ishiko O; Kamiura S; Hasegawa K; Umesaki N
Int J Gynecol Cancer; 2007; 17(1):159-63. PubMed ID: 17291248
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
Nicoletto MO; Falci C; Pianalto D; Artioli G; Azzoni P; De Masi G; Ferrazzi E; Perin A; Donach M; Zoli W
Gynecol Oncol; 2006 Feb; 100(2):318-23. PubMed ID: 16239023
[TBL] [Abstract][Full Text] [Related]
29. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
30. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
Ghamande SA; Piver MS
J Surg Oncol; 1999 Nov; 72(3):162-6. PubMed ID: 10562363
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
de Wit R; van der Burg ME; van den Gaast A; Logmans A; Stoter G; Verweij J
Ann Oncol; 1994 Sep; 5(7):656-7. PubMed ID: 7993845
[TBL] [Abstract][Full Text] [Related]
32. A phase I-II trial of intraperitoneal cisplatin and alpha-interferon in patients with persistent epithelial ovarian cancer.
Berek JS; Welander C; Schink JC; Grossberg H; Montz FJ; Zigelboim J
Gynecol Oncol; 1991 Mar; 40(3):237-43. PubMed ID: 2013446
[TBL] [Abstract][Full Text] [Related]
33. A study of cis-platinum and ifosfamide in alkylating agent-resistant ovarian cancer.
Green JA; Slater AJ
Gynecol Oncol; 1989 Feb; 32(2):233-5. PubMed ID: 2910785
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix.
Fiorica J; Holloway R; Ndubisi B; Orr J; Grendys E; Boothby R; DeCesare S; LaPolla J; Hoffman M; Patel J
Gynecol Oncol; 2002 Apr; 85(1):89-94. PubMed ID: 11925125
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer.
Baekelandt M; Lehne G; Tropé CG; Szántó I; Pfeiffer P; Gustavssson B; Kristensen GB
J Clin Oncol; 2001 Jun; 19(12):2983-93. PubMed ID: 11408493
[TBL] [Abstract][Full Text] [Related]
37. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; Olt G; Lentz SS; Bell J
Gynecol Oncol; 2003 Sep; 90(3):581-6. PubMed ID: 13678728
[TBL] [Abstract][Full Text] [Related]
39. Adriamycin and cis-platinum in advanced ovarian cancer.
de Gramont A; Drolet Y; Lavoie A; Painchaud M; Blouin R; Tessier C; Ouellet P
Eur J Cancer Clin Oncol; 1985 Jun; 21(6):665-9. PubMed ID: 4040466
[TBL] [Abstract][Full Text] [Related]
40. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
